Bayer's chief executive Bill Anderson looks set to keep his role until nearly the decade, as his turnaround plan for the group starts to deliver results. Just over two years into Anderson's tenure, ...

Bayer's much-anticipated stem cell therapy for Parkinson's disease is gathering momentum, with dosing in phase 3 trials now underway. The first patient has already been treated with bemdaneprocel, a ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations for ...